Details of the Drug

General Information of Drug (ID: DMVHGLA)

Drug Name
PB006
Synonyms Natalizumab Biosimilar
Indication
Disease Entry ICD 11 Status REF
Crohn disease DD70 Phase 3 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
DWKI46

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Integrin alpha-4 (ITGA4) TT4BT06 ITA4_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04115488) Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri? in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS). U.S.National Institutes of Health.
2 Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial. JAMA Neurol. 2023 Mar 1;80(3):298-307.